MCID: CNT005
MIFTS: 53

Central Nervous System Lymphoma

Categories: Blood diseases, Cancer diseases, Immune diseases, Neuronal diseases, Rare diseases

Aliases & Classifications for Central Nervous System Lymphoma

MalaCards integrated aliases for Central Nervous System Lymphoma:

Name: Central Nervous System Lymphoma 12 15 17
Primary Central Nervous System Lymphoma 71
Primary Cns Lymphoma 12
Cns Lymphoma 71
Microglioma 12

Classifications:



External Ids:

Disease Ontology 12 DOID:3234
ICD9CM 34 200.5
NCIt 49 C9301
SNOMED-CT 67 307649006
UMLS 71 C0280803 C0742472

Summaries for Central Nervous System Lymphoma

Disease Ontology : 12 A hematologic cancer that has material basis in lymphoma located in central nervous system.

MalaCards based summary : Central Nervous System Lymphoma, also known as primary central nervous system lymphoma, is related to primary central nervous system lymphoma and intraocular lymphoma. An important gene associated with Central Nervous System Lymphoma is MYD88 (MYD88 Innate Immune Signal Transduction Adaptor), and among its related pathways/superpathways are Innate Immune System and ERK Signaling. The drugs Teniposide and Fotemustine have been mentioned in the context of this disorder. Affiliated tissues include central nervous system, brain and b cells, and related phenotypes are Decreased shRNA abundance (Z-score < -2) and Decreased shRNA abundance (Z-score < -2)

Related Diseases for Central Nervous System Lymphoma

Diseases in the Central Nervous System Lymphoma family:

Primary Central Nervous System Lymphoma

Diseases related to Central Nervous System Lymphoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 669)
# Related Disease Score Top Affiliating Genes
1 primary central nervous system lymphoma 34.8 PAX5 MYD88 MGMT CXCR5 CXCL13 BCL6
2 intraocular lymphoma 32.9 PAX5 IL10 CXCR5 CXCL12 BCL6
3 lymphoma, hodgkin, classic 31.4 PAX5 IL2 CD68 CCR6 BCL6
4 histiocytic sarcoma 31.1 CDKN2A CD68
5 uveitis 31.1 IL6 IL2 IL10 CXCR5
6 intravascular large b-cell lymphoma 31.0 MYD88 BCL6
7 follicular lymphoma 30.7 PAX5 MYC CXCR5 BCL6
8 acquired immunodeficiency syndrome 30.7 TP53 MYC IL6 IL2 IL10 CXCR5
9 primary mediastinal large b-cell lymphoma 30.7 CD274 BCL6
10 meningitis 30.7 IL6 IL2 IL10 CXCL13 CXCL12
11 graft-versus-host disease 30.7 IL6 IL2 IL10
12 demyelinating disease 30.6 IL6 IL2 IL10 CCR6
13 neurosyphilis 30.6 IL10 CXCR5 CXCL13
14 anaplastic oligodendroglioma 30.6 MGMT CDKN2A
15 spinal cord lymphoma 30.6 CCR6 BCL6
16 chorioretinitis 30.6 IL6 IL2 IL10
17 immune deficiency disease 30.6 IL6 IL2 IL10 CXCL12 CCR6 BCL6
18 glioblastoma multiforme 30.6 TP53 MYC MGMT IL6 IL2 CXCL12
19 lymphopenia 30.5 IL6 IL2 IL10 CCR6
20 viral encephalitis 30.5 IL6 IL10 CCR6
21 testicular lymphoma 30.5 MYD88 FOXP1 CD274 BCL6
22 posterior uveitis 30.5 IL6 IL2 CCR6
23 chickenpox 30.5 IL6 IL2 IL10 CCR6
24 lymphoplasmacytic lymphoma 30.5 PAX5 MYD88 CXCL12
25 monoclonal paraproteinemia 30.5 PRDM1 PAX5
26 oligodendroglioma 30.5 TP53 MGMT IL2 CDKN2A
27 lymphoblastic lymphoma 30.4 TP53 PAX5 MYC CDKN2A BCL6
28 t-cell adult acute lymphocytic leukemia 30.4 TP53 IL2 CCR6
29 brain stem glioma 30.4 TP53 MGMT CDKN2A
30 spinal cord disease 30.4 IL6 IL2 IL10 CCR6
31 plasmablastic lymphoma 30.3 PRDM1 MYC CDKN2A BCL6
32 orbit lymphoma 30.3 MALT1 FOXP1
33 plasma cell leukemia 30.3 MYC IL6 CDKN2A
34 relapsing-remitting multiple sclerosis 30.3 IL6 IL2 IL10 CCR6
35 panuveitis 30.3 IL6 IL10 CCR6
36 retinal detachment 30.3 TP53 IL6 IL10 CXCL12
37 aphthous stomatitis 30.3 IL6 IL2 IL10
38 t-cell/histiocyte rich large b cell lymphoma 30.3 CD68 BCL6
39 meningoencephalitis 30.3 IL6 IL10 CCR6
40 peripheral t-cell lymphoma 30.3 TP53 PAX5 IL2 CXCL13 CD274 BCL6
41 severe combined immunodeficiency 30.2 IL6 IL2 IL10 CXCL12 CCR6
42 bacterial infectious disease 30.2 MYD88 IL6 IL10 CCR6
43 meningioma, familial 30.2 TP53 MYC MGMT CDKN2A CD68
44 myelitis 30.2 IL6 IL10 CCR6
45 thyroiditis 30.2 IL6 IL2 IL10
46 autoimmune disease 30.2 IL6 IL2 IL10 CD274 CCR6
47 reticulosarcoma 30.2 PAX5 MYC CD68 BCL6
48 candidiasis 30.1 IL6 IL2 IL10 CCR6
49 rubella 30.1 IL6 IL2 IL10
50 crohn's disease 30.0 IL6 IL2 IL10 CCR6

Graphical network of the top 20 diseases related to Central Nervous System Lymphoma:



Diseases related to Central Nervous System Lymphoma

Symptoms & Phenotypes for Central Nervous System Lymphoma

GenomeRNAi Phenotypes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

26 (show all 18)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased shRNA abundance (Z-score < -2) GR00366-A-111 9.6 MGMT
2 Decreased shRNA abundance (Z-score < -2) GR00366-A-12 9.6 CD274
3 Decreased shRNA abundance (Z-score < -2) GR00366-A-120 9.6 CD274 PRDM1
4 Decreased shRNA abundance (Z-score < -2) GR00366-A-149 9.6 PRDM1
5 Decreased shRNA abundance (Z-score < -2) GR00366-A-152 9.6 PRDM1
6 Decreased shRNA abundance (Z-score < -2) GR00366-A-160 9.6 CD274
7 Decreased shRNA abundance (Z-score < -2) GR00366-A-171 9.6 PRDM1
8 Decreased shRNA abundance (Z-score < -2) GR00366-A-179 9.6 PRDM1
9 Decreased shRNA abundance (Z-score < -2) GR00366-A-191 9.6 CD274
10 Decreased shRNA abundance (Z-score < -2) GR00366-A-212 9.6 CD274
11 Decreased shRNA abundance (Z-score < -2) GR00366-A-213 9.6 CD274
12 Decreased shRNA abundance (Z-score < -2) GR00366-A-30 9.6 PRDM1
13 Decreased shRNA abundance (Z-score < -2) GR00366-A-32 9.6 CD274
14 Decreased shRNA abundance (Z-score < -2) GR00366-A-37 9.6 MGMT
15 Decreased shRNA abundance (Z-score < -2) GR00366-A-59 9.6 MGMT
16 Decreased shRNA abundance (Z-score < -2) GR00366-A-60 9.6 PRDM1
17 Decreased shRNA abundance (Z-score < -2) GR00366-A-72 9.6 MGMT
18 Decreased shRNA abundance (Z-score < -2) GR00366-A-99 9.6 PRDM1

MGI Mouse Phenotypes related to Central Nervous System Lymphoma:

45 (show all 14)
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10.42 BCL6 CCR6 CD274 CD68 CDKN2A CXCL12
2 immune system MP:0005387 10.39 BCL6 CCR6 CD274 CD68 CDKN2A CXCL12
3 cellular MP:0005384 10.37 BCL6 CD274 CDKN2A CXCL12 CXCL13 CXCR5
4 cardiovascular system MP:0005385 10.31 BCL6 CCR6 CDKN2A CXCL12 IL10 IL2
5 homeostasis/metabolism MP:0005376 10.29 BCL6 CCR6 CD274 CDKN2A IL10 IL2
6 mortality/aging MP:0010768 10.25 BCL6 CD274 CDKN2A CXCL12 IL10 IL2
7 endocrine/exocrine gland MP:0005379 10.21 BCL6 CDKN2A IL10 IL2 IL6 MGMT
8 liver/biliary system MP:0005370 10.13 BCL6 CDKN2A CXCL12 IL10 IL2 IL6
9 no phenotypic analysis MP:0003012 10.03 BCL6 CD274 CD68 CDKN2A CXCL12 IL10
10 muscle MP:0005369 10.02 BCL6 CDKN2A CXCL12 IL10 IL6 MYC
11 neoplasm MP:0002006 10.02 CDKN2A IL10 IL2 IL6 MGMT MYC
12 normal MP:0002873 9.81 BCL6 CCR6 CXCL12 CXCR5 IL10 MYC
13 reproductive system MP:0005389 9.65 BCL6 CDKN2A CXCL12 IL10 IL2 IL6
14 respiratory system MP:0005388 9.23 BCL6 CDKN2A IL10 IL2 IL6 MGMT

Drugs & Therapeutics for Central Nervous System Lymphoma

Drugs for Central Nervous System Lymphoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 197)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Teniposide Approved Phase 4 29767-20-2 34698
2
Fotemustine Investigational Phase 4 92118-27-9
3 Formoterol Fumarate Phase 4
4
Mechlorethamine Approved, Investigational Phase 3 51-75-2 4033
5
Cefepime Approved, Investigational Phase 3 88040-23-7 5479537
6
Levofloxacin Approved, Investigational Phase 3 100986-85-4 149096
7
Ofloxacin Approved Phase 3 82419-36-1 4583
8
Ketamine Approved, Vet_approved Phase 3 6740-88-1 3821
9
Clotrimazole Approved, Vet_approved Phase 3 23593-75-1 2812
10
Miconazole Approved, Investigational, Vet_approved Phase 3 22916-47-8 4189
11
Ondansetron Approved Phase 3 99614-02-5 4595
12
Dalteparin Approved Phase 3 9005-49-6
13
Tinzaparin Approved Phase 3 9041-08-1, 9005-49-6 25244225
14
Dextromethorphan Approved Phase 3 125-71-3 5360696 5362449
15
Caspofungin Approved Phase 3 162808-62-0, 179463-17-3 2826718 468682
16
Amphotericin B Approved, Investigational Phase 3 1397-89-3 5280965 14956
17
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
18
Idarubicin Approved Phase 2, Phase 3 58957-92-9 42890
19
St. John's Wort Approved, Investigational, Nutraceutical Phase 3 84082-80-4
20 Pancreatic Polypeptide Investigational Phase 3 59763-91-6
21 Cytochrome P-450 Enzyme Inhibitors Phase 3
22 Anesthetics, Dissociative Phase 3
23 Antifungal Agents Phase 3
24 Analgesics Phase 3
25 Cola Phase 3
26 Neurotransmitter Agents Phase 3
27 Liver Extracts Phase 3
28 Analgesics, Opioid Phase 3
29 Psychotropic Drugs Phase 3
30 Anti-Anxiety Agents Phase 3
31 Antipsychotic Agents Phase 3
32 Fibrinolytic Agents Phase 3
33 Anticoagulants Phase 3
34 Heparin, Low-Molecular-Weight Phase 3
35 Antiparasitic Agents Phase 3
36 Antiprotozoal Agents Phase 3
37 Excitatory Amino Acid Antagonists Phase 3
38 Narcotics Phase 3
39 Anesthetics Phase 3
40 Anesthetics, General Phase 3
41 Anesthetics, Intravenous Phase 3
42 Amebicides Phase 3
43 Liposomal amphotericin B Phase 3
44
Serotonin Investigational, Nutraceutical Phase 3 50-67-9 5202
45
tannic acid Approved Phase 1, Phase 2 1401-55-4
46
Benzocaine Approved, Investigational Phase 1, Phase 2 94-09-7, 1994-09-7 2337
47
Mitoxantrone Approved, Investigational Phase 1, Phase 2 65271-80-9 4212
48
Nedaplatin Approved, Investigational Phase 2 95734-82-0
49
Bevacizumab Approved, Investigational Phase 2 216974-75-3
50
Ganciclovir Approved, Investigational Phase 2 82410-32-0 3454

Interventional clinical trials:

(show top 50) (show all 191)
# Name Status NCT ID Phase Drugs
1 The Prospective Study of FVD Program and HD-MTX-Ara-C Program Contrast in the Treatment of PCNSL Lymphoma. Unknown status NCT01960192 Phase 4 HD-MTX-Ara-C regimen;FVD regimen
2 Phase IV Study on the Role of Whole Brain Irradiation in Primary CNS Lymphoma (PCNSL) After High-dose Methotrexate Completed NCT00153530 Phase 4 methotrexate
3 Open Randomized Prospective Clinical Study of Rituximab Combined With Fotemustine, Pemetrexed, Dexamethasone Versus Rituximab Plus Methotrexate, Cytarabine, and Dexamethasone in the Treatment of Primary Central Nervous System Lymphoma Recruiting NCT04083066 Phase 4 rituximab in combination with methotrexate, cytarabine and dexamethasone
4 High-dose Chemotherapy and Autologous Stem Cell Transplant or Consolidating Conventional Chemotherapy in Primary CNS Lymphoma - Randomized Phase III Trial Unknown status NCT02531841 Phase 3 Arm A (Fortecortin®-ETOPOPHOS®-IFO-cell®-CARBO-cell®);Arm B (TEPADINA®-CARMUBRIS®-Busilvex®)
5 Multicenter, Double-Blind, Randomized Study to Compare the Safety and Efficacy of Levofloxacin With That of Cefepime in the Treatment of Fever and Neutropenia - Phase IIIB Unknown status NCT00020865 Phase 3 cefepime hydrochloride;levofloxacin
6 A Randomized Double-Blind Controlled Trial of Ketamine Versus Placebo in Conjunction With Best Pain Management in Neuropathic Pain in Cancer Patients Unknown status NCT01316744 Phase 3 ketamine hydrochloride
7 A Phase III Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Effects of Fragmin (5,000 IU Subcutaneously) in Preventing Catheter-Related Complications When Given Daily to Cancer Patients With Central Venous Catheters Completed NCT00006083 Phase 3 Fragmin
8 Phase III, Randomized, Double-Blind, Placebo-Controlled Crossover Trial of Ondansetron in the Control of Chronic Nausea and Vomiting Not Due to Antineoplastic Therapy in Patients With Advanced Cancer Completed NCT00006348 Phase 3 ondansetron
9 A Phase III Double-Blind Equivalence Study of Two Different Formulations of Slow-Release Morphine Followed by a Randomization Between Dextromethorphan or Placebo Plus Statex SR for Chronic Cancer Pain Relief in Terminally Ill Patients Completed NCT00003687 Phase 3 dextromethorphan hydrobromide;morphine sulfate
10 Does Hypericum Reduce Fatigue in Cancer Patients on Chemotherapy? A Randomized, Double-Blind, Placebo-Controlled Clinical Trial Completed NCT00005805 Phase 3
11 Preparatory Aid to Improve Decision Making About Cancer Clinical Trials (PRE-ACT) Completed NCT00750009 Phase 3
12 A Multicenter, Double-Blind, Randomized, Comparative Study To Evaluate The Safety, Tolerability, And Efficacy Of MK-0991 Versus (Amphotericin B) Liposome For Injection As Empirical Therapy In Patients With Persistent Fever And Neutropenia Completed NCT00008359 Phase 3 caspofungin acetate;liposomal amphotericin B
13 A Randomized, Double-blind, Placebo-controlled Multi-center Study to Evaluate the Safety and Efficacy of Fentanyl Sublingual Spray (Fentanyl SL Spray) for the Treatment of Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
14 Treatment of Primary CNS Lymphoma With Systemic R-IDARAM Chemotherapy and Intrathecal Immunochemotherapy Recruiting NCT02657785 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
15 Therapeutic Effects of R-IDARAM and Intrathecal Immunochemotherapy on Elderly Patients With Primary CNS Lymphoma Recruiting NCT02836158 Phase 2, Phase 3 R-IDARAM plus intrathecal chemotherapy
16 Busulfan+ Cyclophosphamide+ Etoposide Conditioning Regimen for Primary Central Nervous System Lymphoma Undergoing Autologous Hematopoietic Stem Cell Transplantation Recruiting NCT03733327 Phase 2, Phase 3 Busulfan (BU);Cyclophosphamide (CY);Etoposide (VP-16)
17 Phase III Trial Evaluating Maintenance Treatment Versus Observation in Elderly Patients Suffering From Primary Central Nervous System Lymphoma in Complete Remission After High Dose Methotrexate Based Chemotherapy in First Line Recruiting NCT02313389 Phase 3 Rituximab, Methotrexate, Temozolomide
18 Temozolomide in Treatment of Patients With Primary Central Nervous System Lymphoma Unknown status NCT02934204 Phase 2 methotrexate;temozolomide
19 Multicenter Randomized Phase II Study of Methotrexate (MTX) and Temozolomide Versus MTX, Procarbazine, Vincristine and Cytarabine for Primary CNS Lymphoma (PCNSL) in the Elderly Unknown status NCT00503594 Phase 2 Methotrexate and temozolomide;Methotrexate , procarbazine ,vincristine ,cytarabine
20 Treatment of HIV-Related Primary Central Nervous System Lymphoma (HIV-PCNSL): A Phase II Trial With Neoadjuvant Chemotherapy (High-Dose Methotrexate (MTX) Plus High-Dose Zidovudine) and Radiotherapy Unknown status NCT00003261 Phase 2 methotrexate;zidovudine
21 Plasma and Cerebrospinal Fluid (CSF) Pharmacokinetics of Bendamustine as a Component of Salvage Therapy for Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT03392714 Phase 2 R-B(O)AD
22 Ketogenic Diet Adjunctive to High Dose Methotrexate Chemotherapy for Primary Central Nervous System Lymphoma Unknown status NCT02983942 Phase 1, Phase 2
23 MT-R Followed by Autologous Stem Cells Transplantation in Newly-diagnosed Primary Central Nervous System Lymphoma Unknown status NCT02399189 Phase 2 R-MT followed by auto-HSCT
24 Open-label Single Arm Phase II Study on Pembrolizumab for Recurrent Primary Central Nervous System Lymphoma (PCNSL) Unknown status NCT02779101 Phase 2 pembrolizumab
25 Monoinstitutional Phase II Trial Addressing Tolerability and Activity of RCHOP Chemoimmunotherapy Preceded by BBB Permeabilization by t-NGR Necrosis Factor in Patients With Relapsed/Refractory Primary Central Nervous System Lymphoma Unknown status NCT03536039 Phase 2 NGR-hTNF;Doxorubicin;Cyclophosphamide;Vincristine;Prednisone
26 Phase 2 Study of Temsirolimus in Refractory and Recurrent Primary CNS Lymphoma Unknown status NCT00942747 Phase 2 temsirolimus
27 High-Dose Methotrexate Plus Steroid Followed by Concurrent Whole Brain Chemoradiation With Temozolomide for Immunocompetent Patients With Primary Central Nervous System Lymphoma – a Phase II Study Unknown status NCT00455286 Phase 2 Methotrexate;Methylprednisolone;Temozolomide
28 Treatment of Patients Over 65 Years With Primary CNS Lymphoma: High-dose Methotrexate Combined With Chemo-immunotherapy Followed by Maintenance Therapy Unknown status NCT00989352 Phase 2 Methotrexate;Lomustine;Procarbazine;Rituximab
29 Pilot Study Of PMitCEBO Plus G-CSF In Good-Prognosis HIV-Related Lymphoma Unknown status NCT00032149 Phase 1, Phase 2 cyclophosphamide;etoposide;mitoxantrone hydrochloride;prednisolone;vincristine sulfate
30 Phase Ⅱ Trial of Temozolomide Plus Concurrent Whole-Brain Radiation Followed by TNV Regimen as Adjuvant Therapy for Patients With Newly Diagnosed Primary Central Nervous System (CNS) Lymphoma (PCNSL) Unknown status NCT01735747 Phase 2 nedaplatin;vincristine;Temozolomide
31 Low-dose Intra-arterial Bevacizumab for Edema and Radiation Necrosis Therapeutic Intervention (LIBERTI) Unknown status NCT02819479 Phase 2 25% Mannitol;Low-dose Intra-arterial Bevacizumab
32 A Phase II Trial Of Induction Therapy With Zidovudine, Interleukin-2, And Ganciclovir In The Treatment Of HIV Positive Primary Central Nervous System Lymphoma Completed NCT00006264 Phase 2 ganciclovir;zidovudine
33 A Phase 2 Study of Idarubicin Based Combined Modality Therapy in Primary Central Nervous System Lymphoma Completed NCT00193973 Phase 2 Idarubicin, Methotrexate, Filgrastim, intrathecal Ara-C
34 Evaluating the MBVP Chemotherapy Schedule Followed by Consolidating Radiotherapy in Non-AIDS Related Primary Central Nervous System Lymphoma (NAPCL) Completed NCT00003061 Phase 2 cytarabine;methotrexate
35 Phase II Trial of Sequential Chemotherapy and Radiotherapy for AIDS-Related Primary Central Nervous System Lymphoma Completed NCT00000801 Phase 2 Filgrastim;Vincristine sulfate;Doxorubicin hydrochloride;Cyclophosphamide;Cytarabine;Dexamethasone
36 Combination Chemotherapy (Methotrexate, Procarbazine And CCNU), Intraventricular Cytarabine And Methotrexate, +/- Intra-Ocular Chemotherapy For Patients With Primary Central Nervous System Lymphoma Completed NCT00074191 Phase 2 cytarabine;dexamethasone;lomustine;methotrexate;procarbazine hydrochloride
37 Combination Chemotherapy (Methotrexate, Cyclophosphamide, And Etoposide Phosphate) Delivered In Conjunction With Osmotic Blood-Brain Barrier Disruption (BBBD), With Intraventricular Cytarabine +/- Intra-Ocular Chemotherapy, In Patients With Primary Central Nervous System Lymphoma Completed NCT00074178 Phase 2 cyclophosphamide;cytarabine;dexamethasone;etoposide phosphate;methotrexate
38 Randomized Phase II Trial On Primary Chemotherapy With High-Dose Methotrexate And High-Dose Cytarabine With Or Without Thiotepa, And With Or Without Rituximab, Followed By Brain Irradiation Vs. High-Dose Chemotherapy Supported By Autologous Stem Cells Transplantation For Immunocompetent Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT01011920 Phase 2 Methotrexate;Ara-C;Rituximab;Thiotepa;BCNU
39 Open-label, Non-randomized, Phase 2 Study Evaluating Efficacy and Safety of PQR309 in Patients With Relapsed or Refractory Primary Central Nervous System Lymphoma Completed NCT02669511 Phase 2 PQR309
40 Randomized Phase II Trial on Primary Chemotherapy With High-dose Methotrexate, Alone or Associated With High-dose Cytarabine, Followed by Response- and Age-tailored Radiotherapy for Immunocompetent Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00210314 Phase 2 high dose methotrexate;high dose cytarabine
41 A Phase II Trial Of Buparlisib (BKM120) In Patients With Recurrent/Refractory Primary Central Nervous System Lymphoma (PCNSL) and Recurrent/Refractory Secondary Central Nervous System Lymphoma (SCNSL) Completed NCT02301364 Phase 2 Buparlisib (BKM120)
42 Phase I Trial of Escalating High Dose Methotrexate Supported by Glucarpidase to Treat Patients With Primary Central Nervous Lymphoma (PCNSL) Completed NCT00727831 Phase 1, Phase 2 glucarpidase;leucovorin calcium;methotrexate
43 A Phase II Study of Intensive Methotrexate and Cytarabine Followed by High Dose Beam Chemotherapy With Autologous Peripheral Blood Progenitor Cell Transplantation in Patients With Newly Diagnosed Primary Central Nervous System Lymphoma Completed NCT00003632 Phase 2 carmustine;cytarabine;etoposide;melphalan;methotrexate
44 AIDS-Related Primary Central Nervous System Lymphoma: A Phase II Pilot Study of High-Dose Intravenous Methotrexate With Rituximab Leucovorin Rescue and Highly Active Antiretroviral Therapy Completed NCT00267865 Phase 2 Methotrexate;Rituximab;Leucovorin
45 Phase II Study Evaluating the Efficacy of Lenalidomide in Association With Rituximab in Refractory or Relapse of Primary Central Nervous System Lymphoma (PCNSL) Completed NCT01956695 Phase 2 Lenalidomide;Rituximab
46 Phase I/II Study Of Pre-Irradiation Chemotherapy With Methotrexate, Rituximab, And Temozolomide And Post -Irradiation Temozolomide For Primary Central Nervous System Lymphoma Completed NCT00068250 Phase 1, Phase 2 rituximab;methotrexate;temozolomide 100 mg/m^2;temozolomide 150 mg/m^2;temozolomide 200 mg/m^2;post-radiation therapy temozolomide
47 Open-labeled, Multicenter Phase II Study of High-Dose (HD) Methotrexate (MTX) Induction Chemotherapy Followed by Alternative HD MTX-based and HD Cytarabine-based Combination Consolidation Chemotherapy for Newly Diagnosed Primary CNS Lymphoma; CISL 10-01 Study Completed NCT01083342 Phase 2 MTX, MVD, VIA
48 Hydroxyurea Treatment of EBV-Associated Primary CNS Lymphoma in Children and Adults With AIDS Completed NCT00002940 Phase 2 hydroxyurea
49 A Phase II Study of Methotrexate and Thiotepa Chemotherapy for Patients With Newly Diagnosed Primary CNS Lymphoma Completed NCT00045539 Phase 2 leucovorin calcium;methotrexate;thiotepa
50 A Multicenter, Open-label, Noncomparative Study of Enzastaurin in Patients With Non-Hodgkin's Lymphomas Completed NCT00542919 Phase 2 enzastaurin

Search NIH Clinical Center for Central Nervous System Lymphoma

Genetic Tests for Central Nervous System Lymphoma

Anatomical Context for Central Nervous System Lymphoma

The Foundational Model of Anatomy Ontology organs/tissues related to Central Nervous System Lymphoma:

19
Central Nervous System

MalaCards organs/tissues related to Central Nervous System Lymphoma:

40
Brain, B Cells, T Cells, Liver, Bone, Bone Marrow, Endothelial

Publications for Central Nervous System Lymphoma

Articles related to Central Nervous System Lymphoma:

(show top 50) (show all 2643)
# Title Authors PMID Year
1
Eye involvement in primary central nervous system lymphoma. 61
32057762 2020
2
The Challenges of Applying Radiation in Primary Central Nervous System Lymphoma. 61
32531380 2020
3
Effectiveness of digital PCR for MYD88L265P detection in vitreous fluid for primary central nervous system lymphoma diagnosis. 61
32536998 2020
4
Durable Survival Outcomes in Primary and Secondary Central Nervous System Lymphoma After High-dose Chemotherapy and Autologous Stem Cell Transplantation Using a Thiotepa, Busulfan, and Cyclophosphamide Conditioning Regimen. 61
32229199 2020
5
Conventional MR and DW imaging findings of cerebellar primary CNS lymphoma: comparison with high-grade glioma. 61
32561819 2020
6
High incidence of venous thromboembolism and major bleeding in patients with primary CNS lymphoma. 61
32573292 2020
7
Primary Central Nervous System Lymphoma With Diffuse Neurolymphomatosis Involving Multiple Cranial and Spinal Nerve Roots. 61
32332304 2020
8
Correction to: atypical radiological findings of primary central nervous system lymphoma. 61
32211926 2020
9
Pemetrexed in Recurrent or Progressive Central Nervous System Lymphoma: A Phase I Multicenter Clinical Trial. 61
32520407 2020
10
Diagnostic delay and outcome in immunocompetent patients with primary central nervous system lymphoma in Spain: a multicentric study. 61
32524392 2020
11
Expression of hypoxia-inducible factor 1α, glucose transporter 1, and hexokinase 2 in primary central nervous system lymphoma and the correlation with the biological behaviors. 61
32533646 2020
12
Visual hallucinations as psychiatric onset of a primary central nervous system lymphoma: a case report and a brief review of literature on neoplasm-correlated neuropsychiatric disorders. 61
32524322 2020
13
Metabolome Analysis Reveals Excessive Glycolysis via PI3K/AKT/mTOR and RAS/MAPK Signaling in Methotrexate-Resistant Primary CNS Lymphoma-Derived Cells. 61
32108030 2020
14
High-dose methotrexate in ICU patients: a retrospective study. 61
32535662 2020
15
Tirabrutinib: First Approval. 61
32382949 2020
16
Primary dural lymphomas: Clinical presentation, management, and outcome. 61
32176324 2020
17
Risk Factors for Early Mortality in Patients with Primary Central Nervous System Lymphoma: A Large-Cohort Retrospective Study. 61
32251807 2020
18
Primary central nervous system lymphoma: status and advances in diagnosis, molecular pathogenesis, and treatment. 61
32452898 2020
19
A diagnostic challenge of primary Central nervous system lymphoma: from the eyes to the brain. 61
32449877 2020
20
Atypical radiological findings of primary central nervous system lymphoma. 61
32077984 2020
21
Sex-Specific Differences in Primary CNS Lymphoma. 61
32560244 2020
22
On Point in Primary CNS Lymphoma. 61
32510610 2020
23
Early Detection of Secondary Central Nervous System Lymphoma on PET/CT. 61
32149796 2020
24
Ibrutinib in patients with relapsed/refractory central nervous system lymphoma: A retrospective single-centre analysis. 61
32452526 2020
25
Cerebrospinal Fluid Flow Cytometry: Utility in Central Nervous System Lymphoma Diagnosis. 61
32228724 2020
26
Advances and challenges in the treatment of primary central nervous system lymphoma. 61
32420657 2020
27
Maculopathy Associated With Osmotic Blood- Brain Barrier Disruption and Chemotherapy in Patients With Primary CNS Lymphoma. 61
32484895 2020
28
Letter to the Editor Regarding Effects of the COVID-19 Outbreak in Northern Italy: Perspectives from the Bergamo Neurosurgery Department, and the Role of Radiosurgery as a Minimally Invasive Procedure for Primary Central Nervous System Lymphoma in the Pandemic Outbreak. 61
32380338 2020
29
Current status and quality of radiomics studies in lymphoma: a systematic review. 61
32472274 2020
30
Apparent diffusion coefficient as a valuable quantitative parameter for predicting clinical outcomes in patients with newly diagnosed primary CNS lymphoma. 61
32408414 2020
31
Determination of cerebrospinal fluid adenosine deaminase activity cut-off for the diagnosis of tuberculous meningitis in Hong Kong. 61
32423993 2020
32
GSEA-assisted gene signatures valid for combinations of prognostic markers in PCNSL. 61
32439996 2020
33
Cost-effectiveness analysis of rituximab with methotrexate, cytarabine and thiotepa for the treatment of patients with primary central nervous system lymphoma. 61
31931647 2020
34
Health-related quality of life after chemotherapy with or without rituximab in primary central nervous system lymphoma patients: results from a randomised phase III study. 61
32371123 2020
35
Consecutive single-institution case series of primary central nervous system lymphoma treated by R-MPV or high-dose methotrexate monotherapy. 61
32469065 2020
36
Usefulness of carbon-11-labeled methionine positron-emission tomography for assessing the treatment response of primary central nervous system lymphoma. 61
32129443 2020
37
Use of FDG-PET/CT for systemic assessment of suspected primary central nervous system lymphoma: a LOC study. 61
32405997 2020
38
Efficacy and safety of ibrutinib in diffuse large B-cell lymphoma: A single-arm meta-analysis. 61
32540781 2020
39
LCK expression is a potential biomarker for distinguishing primary central nervous system lymphoma from glioblastoma multiforme. 61
32237064 2020
40
Central Nervous System Lymphoma: Approach to Diagnosis and Treatment. 61
32496457 2020
41
Targeting the PI3K/AKT/mTOR Signaling Pathway in Primary Central Nervous System Lymphoma: Current Status and Future Prospects. 61
32416683 2020
42
Clinicopathological characteristics of primary central nervous system lymphoma with low 18F-fludeoxyglucose uptake on brain positron emission tomography. 61
32443328 2020
43
Reduced frequency of Intravitreal methotrexate injection lowers the risk of Keratopathy in Vitreoretinal lymphoma patients. 61
32397978 2020
44
Cell-Block cytology in diagnosis of primary central nervous system lymphoma: A case report. 61
32243381 2020
45
Clinical Characteristics, Surgical Outcomes, and Prognostic Factors of Intracranial Primary Central Nervous System Lymphoma. 61
32311566 2020
46
Allogeneic hematopoietic stem cell transplantation for primary central nervous system lymphoma. 61
31399528 2020
47
A National Consensus Survey for Current Practice in Brain Tumor Management III: Brain Metastasis and Primary Central Nervous System Lymphoma. 61
32390350 2020
48
Patterns of relapse after successful completion of initial therapy in primary central nervous system lymphoma: a case series. 61
32140975 2020
49
Primary therapy and survival in patients aged over 70-years-old with primary central nervous system lymphoma: a contemporary, nationwide, population-based study in the Netherlands. 61
32241841 2020
50
Comparison of Body Size, Morphomics, and Kidney Function as Covariates of High-Dose Methotrexate Clearance in Obese Adults with Primary Central Nervous System Lymphoma. 61
32090349 2020

Variations for Central Nervous System Lymphoma

Cosmic variations for Central Nervous System Lymphoma:

9
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)
Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM105231581 MYD88 haematopoietic and lymphoid tissue,central nervous system,lymphoid neoplasm,primary central nervous system lymphoma c.818T>C p.L273P 3:38141150-38141150 0

Copy number variations for Central Nervous System Lymphoma from CNVD:

7
# CNVD ID Chromosome Start End Type Gene Symbol CNVD Disease
1 250739 9 21967751 21994490 Methylation deletion CDKN2A CNS lymphoma

Expression for Central Nervous System Lymphoma

Search GEO for disease gene expression data for Central Nervous System Lymphoma.

Pathways for Central Nervous System Lymphoma

Pathways related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 44)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
14.03 TP53 MYD88 MYC MALT1 IL6 IL2
2
Show member pathways
13.79 TP53 MYC IL6 IL2 IL10 CXCR5
3
Show member pathways
13.65 TP53 MYC IL6 IL2 IL10 CXCR5
4
Show member pathways
13.34 TP53 MYD88 MYC IL6 IL2 IL10
5
Show member pathways
13.27 IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
6
Show member pathways
13.26 TP53 MYD88 IL6 IL2 IL10 CXCR5
7
Show member pathways
13.03 TP53 MYD88 MYC IL6 IL2 IL10
8
Show member pathways
12.91 TP53 MYD88 MYC IL6 CXCL12 CDKN2A
9 12.8 TP53 MYC IL6 IL2 CXCL12 CDKN2A
10
Show member pathways
12.79 TP53 MYD88 MYC IL6 IL2
11
Show member pathways
12.78 IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
12
Show member pathways
12.67 MYD88 MALT1 IL6 IL2 CXCL12
13
Show member pathways
12.55 TP53 MYC IL6 IL2 IL10
14
Show member pathways
12.42 MYC IL6 IL2 IL10 CXCL12
15
Show member pathways
12.42 MYD88 MALT1 IL6 IL2 IL10 CD274
16 12.23 TP53 MYC IL6 IL2 CDKN2A
17 12.21 MYD88 MALT1 IL6 IL10
18 12.13 TP53 MYC IL6 CDKN2A
19 12.11 TP53 PAX5 MYC IL6 BCL6
20
Show member pathways
12.01 TP53 MYC IL6 IL2 IL10 CXCL12
21
Show member pathways
12 MYD88 MALT1 IL6 IL2 IL10
22 11.97 MYD88 IL6 IL2 IL10
23 11.96 TP53 MYC IL6 IL2
24 11.94 IL6 IL2 IL10 CD68
25 11.93 TP53 MYC CDKN2A BCL6
26 11.88 TP53 MYC MGMT CDKN2A
27 11.84 PRDM1 PAX5 MYD88 MALT1 IL2 IL10
28
Show member pathways
11.83 IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
29
Show member pathways
11.78 IL2 CXCL13 CXCL12
30 11.78 TP53 IL6 IL2
31 11.74 MYD88 IL6 IL10
32 11.72 IL6 IL2 IL10
33
Show member pathways
11.71 TP53 PRDM1 CDKN2A
34 11.71 TP53 MYC CDKN2A
35 11.68 IL2 IL10 CXCR5 CCR6
36 11.61 TP53 MYC IL6 IL10 BCL6
37 11.53 TP53 MYC IL6
38 11.52 MYD88 IL6 IL10
39 11.36 MYD88 IL6 IL10
40 11.33 MYC IL6 IL10
41 11.27 TP53 IL6 IL2 CDKN2A
42 11.19 IL6 IL2 IL10
43
Show member pathways
11.04 TP53 MYC CDKN2A
44 11.03 TP53 MYC CDKN2A

GO Terms for Central Nervous System Lymphoma

Cellular components related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cell GO:0005623 9.23 MYC IL6 IL2 CXCR5 CXCL13 CXCL12

Biological processes related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

(show all 25)
# Name GO ID Score Top Affiliating Genes
1 positive regulation of transcription by RNA polymerase II GO:0045944 10.14 TP53 PAX5 MYC IL6 IL2 IL10
2 cellular response to DNA damage stimulus GO:0006974 10.02 TP53 MYC MGMT FOXP1 BCL6
3 negative regulation of cell proliferation GO:0008285 10 TP53 IL6 IL10 CDKN2A BCL6
4 positive regulation of gene expression GO:0010628 9.95 TP53 PRDM1 MYD88 MYC IL6 CDKN2A
5 regulation of gene expression GO:0010468 9.92 PRDM1 MYD88 MYC IL10 FOXP1
6 regulation of cell proliferation GO:0042127 9.91 TP53 PRDM1 MYD88 BCL6
7 immune response GO:0006955 9.86 IL6 IL2 IL10 CXCR5 CXCL13 CXCL12
8 chemotaxis GO:0006935 9.84 CXCR5 CXCL13 CXCL12 CCR6
9 positive regulation of cytosolic calcium ion concentration GO:0007204 9.81 IL2 CXCR5 CXCL13 CCR6
10 positive regulation of T cell proliferation GO:0042102 9.75 IL6 IL2 CD274
11 humoral immune response GO:0006959 9.73 PAX5 IL6 CCR6
12 cell chemotaxis GO:0060326 9.73 CXCR5 CXCL13 CXCL12 CCR6
13 chemokine-mediated signaling pathway GO:0070098 9.71 CXCR5 CXCL13 CXCL12 CCR6
14 cytokine-mediated signaling pathway GO:0019221 9.7 TP53 MYD88 MYC IL6 IL2 IL10
15 positive regulation of smooth muscle cell proliferation GO:0048661 9.67 MYD88 MYC IL6 FOXP1
16 leukocyte chemotaxis GO:0030595 9.63 IL10 CXCR5 CXCL13
17 positive regulation of production of miRNAs involved in gene silencing by miRNA GO:1903800 9.62 TP53 IL6
18 regulation of tumor necrosis factor production GO:0032680 9.61 MYD88 FOXP1
19 negative regulation of apoptotic process GO:0043066 9.61 TP53 MYD88 MYC MGMT MALT1 IL6
20 germinal center formation GO:0002467 9.58 CXCL13 BCL6
21 response to peptidoglycan GO:0032494 9.57 MYD88 IL6
22 type 2 immune response GO:0042092 9.55 IL10 BCL6
23 negative regulation of B cell apoptotic process GO:0002903 9.5 IL2 FOXP1 BCL6
24 regulation of chemokine (C-X-C motif) ligand 2 production GO:2000341 9.49 MYD88 FOXP1
25 cellular response to lipopolysaccharide GO:0071222 9.17 MYD88 MALT1 IL6 IL10 CXCL13 CD68

Molecular functions related to Central Nervous System Lymphoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 growth factor activity GO:0008083 9.56 IL6 IL2 IL10 CXCL12
2 cytokine activity GO:0005125 9.55 IL6 IL2 IL10 CXCL13 CXCL12
3 kinase activator activity GO:0019209 9.32 MALT1 IL2
4 core promoter sequence-specific DNA binding GO:0001046 9.13 TP53 MYC FOXP1
5 protein self-association GO:0043621 8.92 TP53 MYD88 MALT1 FOXP1

Sources for Central Nervous System Lymphoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....